What is the GMP of Molbio Diagnostics IPO today?

As of 14 Aug 2026, 08:48 AM IST, the median GMP of Molbio Diagnostics IPO across 5 public tracker(s) is ₹156, with individual trackers quoting between ₹146 and ₹157. That implies an estimated listing gain of about 19.33% — an unofficial market signal, not a guarantee.

Is GMP a reliable indicator?

Partially. GMP correlates with listing gains on large liquid IPOs but is far less reliable on SME issues, where trackers can disagree widely and thin grey markets can be manipulated. That is why we publish the median, the full range and a confidence grade instead of a single number.

Molbio Diagnostics IPO GMP Today

Updated 14 Aug 2026, 08:48 AM IST

Median GMP ₹156 across 5 trackers

Range ₹146–157 trackers broadly agree

Est. listing gain +19.33% vs issue price ₹807

Subscription 70.26× Mainboard · Closed · 10-12 August

How much should you trust this number?

high confidence

Coverage 92

Agreement 86

Stability 77

Weighted 40 / 40 / 20 into the score. High ≥70 · Medium 45–69 · Low <45 — full recipe in the methodology.

GMP trend — daily median with tracker range

Date	Median	Range	Sources
2026-08-14	₹156	₹146–157	5
2026-08-13 est.	₹156	₹156–156	1
2026-08-12 est.	₹138	₹138–138	1
2026-08-11 est.	₹127	₹127–127	1
2026-08-10 est.	₹132	₹132–132	1
2026-08-08 est.	₹180	₹180–180	1
2026-08-07 est.	₹220	₹220–220	1

What each tracker says

No official GMP exists, so we show you every source we aggregate — ordered by tracker size, linked so you can verify. Judge the number by its spread, not our word.

IPO Jiestablished tracker ₹146 -6%

IPO Watchestablished tracker ₹156 +0%

Chanakya Ni Pothimid-size tracker ₹156 +0%

IPO Indexmid-size tracker ₹155 -1%

IPO 360smaller tracker ₹157 +1%

median across trackers · bar length is each tracker's quote · % is deviation from the median

How to read this

Multiple trackers agree closely on Molbio Diagnostics's GMP, so the median is a comparatively steady signal today. GMP reflects unofficial demand, not fundamentals — read the RHP, check subscription figures on NSE/BSE, and decide on the company, not the premium.